During the last 15 years, researchers have shown that a large percentage of persons with severe or profound mental retardation or multiple handicaps have serious sleep problems. These problems can cause emotional and physical burdens for caretakers, interfere with the persons' daily learning and occupational performance, and/or exacerbate deviant behaviors. Several studies have been conducted to assess behavioral and pharmacological strategies (e.g., bedtime fading and response cost, extinction, chronotherapy, and the use of melatonin) for reducing sleep problems. Those studies are reviewed here and the effectiveness, suitability, practicality, and acceptability of the strategies are discussed. Relevant issues for future research are also examined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1352/0895-8017(1999)104<0170:ROSFTS>2.0.CO;2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Calcineurin governs baseline and homeostatic regulations of non-rapid eye movement sleep in mice.
Proc Natl Acad Sci U S A
January 2025
National Institute of Biological Sciences, Beijing 102206, China.
Sleep need accumulates during waking and dissipates during sleep to maintain sleep homeostasis (process S). Besides the regulation of daily (baseline) sleep amount, homeostatic sleep regulation commonly refers to the universal phenomenon that sleep deprivation (SD) causes an increase of sleep need, hence, the amount and intensity of subsequent recovery sleep. The central regulators and signaling pathways that govern the baseline and homeostatic sleep regulations in mammals remain unclear.
View Article and Find Full Text PDFEvolution of sleep disordered breathing in infants with achondroplasia.
Sleep Breath
January 2025
McGovern Medical School University of Texas Health, Houston, TX, USA.
Purpose: Children with achondroplasia (ACH) are at risk for sudden death in infancy due to sleep disordered breathing (SDB) and foramen magnum stenosis (FMS). Sleep studies and neuroimaging are performed in infants with ACH, but interpretation of infant studies is challenging. We sought to describe baseline data on polysomnography (PSG) indices in infants with achondroplasia as well as effects of age and surgery on these parameters.
View Article and Find Full Text PDFLong-Term Management of Sleep Apnea-Hypopnea Syndrome: Efficacy and Challenges of Continuous Positive Airway Pressure Therapy-A Narrative Review.
Med Sci (Basel)
December 2024
Department of Medicine, Universidad Nacional Autonoma de México (UNAM), Mexico City 04510, Mexico.
Sleep apnea-hypopnea syndrome (SAHS) is a respiratory disorder characterized by cessation of breathing during sleep, resulting in daytime somnolence and various comorbidities. SAHS encompasses obstructive sleep apnea (OSA), caused by upper airway obstruction, and central sleep apnea (CSA), resulting from lack of brainstem signaling for respiration. Continuous positive airway pressure (CPAP) therapy is the gold standard treatment for SAHS, reducing apnea and hypopnea episodes by providing continuous airflow.
View Article and Find Full Text PDFPolice Contact, Sleep, and Mental Health in the Adolescent Brain Cognitive Development (ABCD) Study.
J Community Psychol
January 2025
Department of Psychology, University of Tennessee, Knoxville, Tennessee, USA.
Using data from the Adolescent Brain Cognitive Development study (n = 3928), we examined how police contact relates to sleep problems, anxiety, and depressive symptoms during middle adolescence (M age = 14.09; SD = 0.68).
View Article and Find Full Text PDFIncident Cheyne-Stokes respiration occurring in CPAP-treated patients and cardiovascular risk: a 2-years prospective follow-up (The Alertapnee study).
Respir Res
January 2025
HP2 Laboratory, Inserm Unit 1300, University Grenoble Alpes, Grenoble, France.
The Alertapnée study followed 555 adults with obstructive sleep apnea treated with CPAP and found that the occurrence of Cheyne-Stokes respiration (CSR) was linked to a 14-fold increase in the risk of significant cardiac events (SCE) after one year. However, the progression and clinical significance of CSR episodes over time remain unclear. This ancillary study aimed to assess CSR progression and clinical outcomes during a second year of follow-up in 66 patients who had experienced at least one CSR episode in the first year.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!